June 23, 2017
Antibe Therapeutics Announces Closing of Public Offering
Toronto, ON – (June 21, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the first closing of its previously announced marketed public offering of units (the “Units”) for gross proceeds of approximately $4,050,000 (the “Offering”).
Read the full press release here.
